Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial.
PLoS Med. 2016 Oct 11;13(10):e1002139. doi: 10.1371/journal.pmed.1002139. eCollection 2016 Oct.
PLoS Med. 2016.
PMID: 27727279
Free PMC article.
Clinical Trial.
Effective recruitment of participants to a phase I study using the internet and publicity releases through charities and patient organisations: analysis of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D).
Heywood J, Evangelou M, Goymer D, Kennet J, Anselmiova K, Guy C, O'Brien C, Nutland S, Brown J, Walker NM, Todd JA, Waldron-Lynch F.
Heywood J, et al. Among authors: anselmiova k.
Trials. 2015 Mar 11;16:86. doi: 10.1186/s13063-015-0583-7.
Trials. 2015.
PMID: 25881192
Free PMC article.
Clinical Trial.
Item in Clipboard
The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes.
Seelig E, Howlett J, Porter L, Truman L, Heywood J, Kennet J, Arbon EL, Anselmiova K, Walker NM, Atkar R, Pekalski ML, Rytina E, Evans M, Wicker LS, Todd JA, Mander AP, Bond S, Waldron-Lynch F.
Seelig E, et al. Among authors: anselmiova k.
JCI Insight. 2018 Oct 4;3(19):e99306. doi: 10.1172/jci.insight.99306.
JCI Insight. 2018.
PMID: 30282826
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite